CCND1 and breast carcinoma: The importance of improved understanding of cyclin D1 signaling in cancer has recently been underscored due to the introduction of a new class of antineoplastic drugs, the CDK 4/6 inhibitors targeting cell cycle activation by cyclin D1 in breast cancer and other malignant diseases [3].